Caplin Point Laboratories (524742) Q4 25/26 earnings summary

Executive summary

• Revenue doubled over five years, reaching ₹2,303 Crores in FY26, up 13.2% YoY, with PAT at ₹650 Crores, a 20.1% increase, and free cash reserves at ₹1,471 Crores; company remains debt-free.

• Strong expansion in injectables, automation, and digitalization, with 17 lines planned for regulated markets and significant investments in manufacturing and product development.

• Expansion into new geographies, especially Latin America, US, Canada, Australia, and Brazil, with robust product registrations and pipeline.

• Strong focus on R&D, women empowerment, ESG, and disciplined operational practices, including rural healthcare and waste recycling initiatives.

• Recognized in Business Standard 1000 and Forbes Asia's 200 Best Under a Billion for the seventh time.

Financial highlights

• FY26 revenue from operations rose 12.9% YoY to ₹2,187.2 Crores; PAT increased 20.1% to ₹650 Crores; EBITDA grew 17.9% to ₹876.4 Crores; gross margin at 60.4%.

• EBITDA margin improved to 38.1% in FY26 from 36.5% in FY25; PAT margin at 28.2%.

• Free cash reserves at ₹1,471 Crores and liquid assets at ₹2,726 Crores as of March 31, 2026.

• Cash flow from operations was ₹523 Crores, with free cash flow after capex at ₹275 Crores.

• R&D spend crossed ₹100 Crores, representing 4.6% of operating revenue.

Outlook and guidance

• Confident in sustaining double-digit revenue growth, with expectations of 25%-30% growth in the US business and plans to double own-label revenue.

• Focus on complex and differentiated products, automation, backward integration, and digital transformation.

• Capex budget of over ₹1,000 Crores for capacity expansion and backward integration, funded entirely by internal accruals.

• PAT margins expected to remain in the 25%-29% range over the next several years.

• Company expects to remain net cash positive throughout the investment cycle.